Human TSLP Protein, His Tag, premium grade
分子別名(Synonym)
TSLP
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human TSLP Protein, His Tag, premium grade (TSP-H52Hb) is expressed from human 293 cells (HEK293). It contains AA Tyr 29 - Gln 159 (Accession # Q969D9-1).
Predicted N-terminus: Tyr 29
該產(chǎn)品是在我們嚴(yán)格的質(zhì)量控制體系下生產(chǎn)的,該體系包括一套全面的檢測,包括無菌和內(nèi)毒素檢測。在臨床前早期階段,仔細(xì)驗證產(chǎn)品性能,并測試其與細(xì)胞培養(yǎng)用途或任何其他應(yīng)用的兼容性。當(dāng)準(zhǔn)備好過渡到后期臨床階段時,我們還提供定制的GMP蛋白質(zhì)服務(wù),以滿足您的需求。我們將與您合作,根據(jù)您的要求定制和開發(fā)GMP級產(chǎn)品,該產(chǎn)品也符合細(xì)胞治療的細(xì)胞制造中使用的原材料和輔助材料的要求。
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 16.8 kDa. The protein migrates as 20-27 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 0.1 EU per μg by the LAL method.
無菌(Sterility)
Negative
支原體(Mycoplasma)
Negative.
純度(Purity)
>90% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 24 months under sterile conditions after reconstitution.
背景(Background)
胸腺基質(zhì)淋巴細(xì)胞生成素(TSLP)是一種上皮細(xì)胞衍生的細(xì)胞因子,參與炎癥性皮膚病的病理過程,并在上皮細(xì)胞中廣泛表達(dá)。人TSLP cD編碼一個159個氨基酸(aa)殘基的前體蛋白,具有28個aa的信號序列(4,5)。人類TSLP已被證明可以發(fā)展非損傷性中樞耐受,放大上皮誘導(dǎo)的類別轉(zhuǎn)換,誘導(dǎo)特應(yīng)性疾病,并維持腸道非炎癥環(huán)境。在對人TSLP有反應(yīng)的多種細(xì)胞中,CD11c+樹突狀細(xì)胞是最明顯的靶細(xì)胞。
關(guān)鍵字: TSLP;TSLP蛋白;TSLP重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。